Understanding how B-cell lymphoma evades the immune system
Official title: A Novel Mechanism of Immune Escape by B-cell Lymphoma
Funded at Ralph H Johnson VA Medical Center · NIH-10951499 · Data updated 2026-11-12
This study is looking at how certain blood cancers called B-cell lymphomas hide from the immune system and how a molecule named FCRLA helps them do that, with the goal of finding new ways to boost the immune response and improve treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ralph H Johnson VA Medical Center NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX006101-02 |
| Project ID | NIH-10951499 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with B-cell lymphoma who may benefit from new immunotherapy approaches.
✕Less likely to help
Patients with other types of cancers or those without B-cell lymphoma may not receive direct benefits from this research.
What this research studies
This research investigates how B-cell lymphomas develop mechanisms to escape detection by the immune system, particularly focusing on the role of a molecule called FCRLA. The study aims to understand how this molecule impairs the ability of immune cells to recognize and attack the tumor. By blocking the effects of FCRLA, the researchers hope to enhance the immune response against B-cell lymphomas, potentially leading to more effective treatments. Patients may be involved in trials that explore new therapies targeting this immune evasion mechanism.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with B-cell lymphoma by enhancing their immune response against the cancer.
How similar studies have gone: Other research has shown promise in targeting immune evasion mechanisms in cancers, suggesting that this approach could be effective.
Where this research is happening
-
Ralph H Johnson VA Medical Center
Charleston, United States Active
Researchers
- Principal investigator: Haque, Azizul — Ralph H Johnson VA Medical Center
- Study coordinator: Haque, Azizul
Related research
Other NIH-funded projects on the same topics.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
Spatially resolved single-cell biomarkers to guide B cell lymphoma therapy
Aims to map tiny details in the tumor and immune cells of diffuse large B-cell lymphoma to help predict outcomes and guide treatments.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.